AI assistant
Sending…
BridgeBio Pharma, Inc. — Director's Dealing 2025
Jun 30, 2025
30604_dirs_2025-06-30_5c9ae800-682a-4654-b29b-efc28fa501aa.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4/A — Form 4/A
Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2021-12-29
Reporting Person: Valantine Hannah (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-12-29 | Common Stock | P | 1752 | $14.24 | Acquired | 3294 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 2687 | Indirect |
More from BridgeBio Pharma, Inc.
Regulatory Filings
2026
May 27
Regulatory Filings
2026
May 13
Regulatory Filings
2026
May 8
Interim / Quarterly Report
2026
May 7
Regulatory Filings
2026
May 7
Annual Report
2026
Apr 24
Proxy Solicitation & Information Statement
2026
Apr 24
Director's Dealing
2026
Mar 20
Director's Dealing
2026
Mar 20
Director's Dealing
2026
Mar 3